#China #biopharmaceuticals #Hangzhou #Clinical Trials #Tigermed

Tigermed's 2026 Interim Results: A Strong Showing in the Biopharmaceutical Landscape

On August 28, 2026, Hangzhou Tigermed Consulting Co., Ltd., a prominent player in integrated research and development solutions for the biopharmaceutical and medical device sectors, disclosed its interim results for the year. The report indicates a robust revenue performance with significant year-over-year growth across multiple sectors, marking a promising trend for the company's future.

Financial Highlights

Within the first half of 2026, Tigermed achieved remarkable revenue figures, recording RMB 3,707.6 million, which represents a 14.1% increase compared to the previous year. The gross profit also saw a healthy rise to RMB 1,020.5 million, up by 4.4%. Additionally, the adjusted net profit attributable to the company's owners surged by 31.8%, reaching RMB 277.7 million.

The clinical trial solutions segment was a notable contributor to this growth, generating revenue of RMB 1,773.4 million, reflecting a year-over-year growth of 20.7%. Furthermore, the clinical-related and lab services segment followed closely, registering a revenue of RMB 1,934.2 million, an increase of 8.6%.

In terms of geographic performance, Tigermed's revenue in China reached RMB 2,106.1 million, marking an impressive 24.0% growth year-over-year, while its overseas revenue amounted to RMB 1,601.5 million, with a modest growth of 3.2%.

Business Development and Collaborations

The company's significant advancements in the second quarter of 2026 included strategic partnerships with several major players, such as Hisun Pharmaceutical and Insilico Medicine. These collaborations are focused on enhancing clinical trials and integrating artificial intelligence into research and development processes. Moreover, Tigermed completed the acquisitions of Teddy Laboratory and Shanghai Bioquick, substantially expanding its capabilities from preclinical research to clinical supply chain operations.

A pivotal moment for the company was the opening of its new global headquarters and Tigermed Park in Hangzhou, designed to foster innovation and strengthen global operations. As of mid-2026, Tigermed employed nearly 12,000 people worldwide, with a strong international presence that includes 2,019 staff located outside of China. The company has been instrumental in supporting the research and development of 31 approved Class 1 new drugs in China, evidencing its expertise in the sector.

Clinical Trial Solutions and Innovations

By the end of June 2026, Tigermed was managing 667 ongoing drug clinical research projects, serving over 1,000 clients in regulatory affairs. In the medical device sector, more than 600 professionals were hard at work, helping to launch five industry-first products in the first half of the year.

The company also enhanced its clinical-related and lab services, with a client base of over 440 for data management and statistical analysis, managing a total of 1,126 projects. With substantial facilities across North America and Europe, the global laboratory services team has surpassed 1,800 personnel, reflecting Tigermed’s commitment to maintaining robust operational capability across regions.

Advancements in Digital Innovation

Tigermed is not just focused on traditional methods but is also at the forefront of integrating digital technologies within clinical research. The establishment of an intelligent clinical research platform leveraging decentralized clinical trials (DCTs) and AI technologies represents the company’s stride towards modernization and efficiency in their research efforts. In 2026's first half, numerous DCT projects were initiated, focusing on enhancing patient recruitment and retention through digital tools.

Management Insights

Dr. Xiaoping Ye, co-founder and chairman, emphasized the importance of innovation and collaboration as drivers for growth within the biopharmaceutical industry. The company will continue to advance its professional capabilities and seek opportunities to remain a competitive player globally. Similarly, other executives underlined the necessity for sustainable and high-quality growth, ensuring long-term value creation for clients and stakeholders alike.

Conclusion

Overall, Tigermed’s interim report for 2026 heralds a period of substantial growth and strategic advancement in an ever-evolving industry. The company's proactive approach in integrating cutting-edge technology and forming beneficial partnerships positions it for continued success in the biopharmaceutical landscape. The outlook for Tigermed appears bright as it leverages its strengths to meet global health challenges head-on.